AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA”
May. 29, 2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Featured image for “The Importance of Self-Advocacy”
May. 26, 2026

The Importance of Self-Advocacy

Featured image for “Webinar: Post-ASCO Melanoma Research Update”
May. 21, 2026

Webinar: Post-ASCO Melanoma Research Update

Featured image for “Melanoma Monday: Every Day. Everywhere.”
May. 04, 2026

Melanoma Monday: Every Day. Everywhere.

Featured image for “Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event”
Apr. 27, 2026

Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event

Filter by Tag